Replies to post #241284 on Biotech Values

[DewDiligence]

OPK, MRK collaborate on Epstein-Barr vaccine—$50M up-front cash to OPK:

https://finance.yahoo.com/news/opko-health-modex-therapeutics-enters-130000637.html

OPKO Health…today announced that ModeX Therapeutics, Inc., an OPKO Health company, entered into an exclusive worldwide license and collaboration agreement with Merck…for the development of MDX-2201, ModeX’s preclinical nanoparticle vaccine candidate targeting EBV.

There is no currently no approved vaccine for EBV.